{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:46:54Z","timestamp":1758635214653,"version":"3.40.5"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Renal Nutrition"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1053\/j.jrn.2014.10.026","type":"journal-article","created":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T15:57:19Z","timestamp":1420559839000},"page":"194-200","source":"Crossref","is-referenced-by-count":19,"title":["Nephroprotective Action of Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease Patients: The Landscape After ALTITUDE and VA NEPHRON-D Trails"],"prefix":"10.1053","volume":"25","author":[{"given":"Boleslaw","family":"Rutkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Tylicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jrn.2014.10.026_bib1","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: overview of the renin-angiotensin system\u2014an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"key":"10.1053\/j.jrn.2014.10.026_bib2","doi-asserted-by":"crossref","first-page":"p3","DOI":"10.1159\/000066656","article-title":"The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology","volume":"93","author":"Wolf","year":"2003","journal-title":"Nephron Physiol"},{"key":"10.1053\/j.jrn.2014.10.026_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s101570170012","article-title":"Mechanisms that control glomerular hemodynamics","volume":"5","author":"Arima","year":"2001","journal-title":"Clin Exp Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib4","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/ki.1997.480","article-title":"Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts","volume":"52","author":"Ruiz-Ortega","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1525-1381.1999.99117.x","article-title":"Angiotensin II induces alpha3(IV) collagen expression in cultured murine proximal tubular cells","volume":"111","author":"Wolf","year":"1999","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1053\/j.jrn.2014.10.026_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1091\/mbc.2.3.219","article-title":"Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells","volume":"2","author":"Wolf","year":"1991","journal-title":"Cell Regul"},{"key":"10.1053\/j.jrn.2014.10.026_bib7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/ki.1995.150","article-title":"ECM degradation by cultured human mesangial cells is mediated by a PA\/plasmin\/MMP-2 cascade","volume":"47","author":"Baricos","year":"1995","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1523-1755.1999.00578.x","article-title":"Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells","volume":"56","author":"Gesualdo","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ki.1994.67","article-title":"Osteopontin expression in\u00a0angiotensin II-induced tubulointerstitial nephritis","volume":"45","author":"Giachelli","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000020513","article-title":"AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis","volume":"6","author":"Wolf","year":"1998","journal-title":"Exp Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1172\/JCI119615","article-title":"Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor","volume":"100","author":"Wolf","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jrn.2014.10.026_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1523-1755.1998.00068.x","article-title":"Angiotensin II induces superoxide anion production by mesangial cells","volume":"54","author":"Jaimes","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1073\/pnas.93.1.156","article-title":"Angiotensin II type 2 receptor mediates programmed cell death","volume":"93","author":"Yamada","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jrn.2014.10.026_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.HYP.35.1.68","article-title":"Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells","volume":"35","author":"Ohnaka","year":"2000","journal-title":"Hypertension"},{"key":"10.1053\/j.jrn.2014.10.026_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"10.1053\/j.jrn.2014.10.026_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/01.HYP.20.1.67","article-title":"Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses","volume":"20","author":"Ullian","year":"1992","journal-title":"Hypertension"},{"key":"10.1053\/j.jrn.2014.10.026_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0895-7061(04)00811-8","article-title":"Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotension system","volume":"17","author":"Iglarz","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.jrn.2014.10.026_bib19","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.jrn.2014.10.026_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2009030300","article-title":"The biology of the (pro)renin receptor","volume":"21","author":"Nguyen","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1046\/j.1523-1755.2000.00031.x","article-title":"Renoprotective benefits of ras inhibition: from ACEI to angiotensin II antagonists","volume":"57","author":"Taal","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5301\/JN.2011.6445","article-title":"Renal protection with angiotensin receptor blockers: where do we stand","volume":"24","author":"Schmieder","year":"2012","journal-title":"J Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1046\/j.1523-1755.2000.00983.x","article-title":"Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology","volume":"57","author":"Delyani","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib24","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"10.1053\/j.jrn.2014.10.026_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5301\/jn.5000008","article-title":"Aliskiren: the first direct renin inhibitor available for clinical use","volume":"24","author":"Morganti","year":"2011","journal-title":"J Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib29","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib30","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.jrn.2014.10.026_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ace-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.jrn.2014.10.026_bib32","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.jrn.2014.10.026_bib33","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"key":"10.1053\/j.jrn.2014.10.026_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000065227","article-title":"Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis","volume":"22","author":"Tylicki","year":"2002","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.1994.113","article-title":"Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system ?","volume":"45","author":"Gansevoort","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib39","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib40","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s11255-011-0110-z","article-title":"Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial","volume":"44","author":"Lizakowski","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib41","doi-asserted-by":"crossref","first-page":"900","DOI":"10.5301\/jn.5000134","article-title":"Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions","volume":"25","author":"Tylicki","year":"2012","journal-title":"J Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","article-title":"Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease","volume":"2001","author":"Shiigai","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2014.10.026_bib43","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2013.355","article-title":"Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?","volume":"85","author":"Sarafidis","year":"2013","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib44","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1097\/01.ASN.0000097862.14805.06","article-title":"Regression lines in chronic kidney disease","volume":"14","author":"Fogo","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib45","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1046\/j.1523-1755.1998.00164.x","article-title":"Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade","volume":"54","author":"Peters","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib46","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1097\/01.ASN.0000095248.91994.D3","article-title":"Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats","volume":"14","author":"Adamczak","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/01.ASN.0000060574.38107.3B","article-title":"Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases","volume":"14","author":"Boffa","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib48","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1046\/j.1523-1755.2000.00426.x","article-title":"Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1","volume":"58","author":"Ma","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib49","first-page":"35","article-title":"Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function","volume":"14","author":"Palla","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"issue":"Suppl. 1","key":"10.1053\/j.jrn.2014.10.026_bib50","first-page":"S196","article-title":"The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion","volume":"2","author":"Weinberg","year":"2002","journal-title":"JRAAS"},{"key":"10.1053\/j.jrn.2014.10.026_bib51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/ajkd.2002.34883","article-title":"Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy","volume":"40","author":"Haas","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2014.10.026_bib52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/00365590801905943","article-title":"Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study","volume":"42","author":"Tylicki","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00041552-200207000-00001","article-title":"Combination ACEI and ARB therapy: additional benefit in renoprotection","volume":"11","author":"Taal","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.jrn.2014.10.026_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2010.226","article-title":"Dual RAAS blockade is desirable in kidney disease: con","volume":"78","author":"Bakris","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2014.10.026_bib55","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.ajkd.2003.10.032","article-title":"Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis","volume":"43","author":"Rutkowski","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2014.10.026_bib56","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000343391","article-title":"The enhanced renin-angiotensin-aldosteron system pharmacological blockade\u2014which is the best?","volume":"36","author":"Tylicki","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1053\/j.jrn.2014.10.026_bib58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2014.10.026_bib59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.jrn.2014.10.026_bib60","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.jrn.2014.10.026_bib61","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","article-title":"Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial","volume":"52","author":"Tylicki","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.jrn.2014.10.026_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.jrn.2014.10.026_bib63","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMe1312286","article-title":"The end of dual therapy with renin-angiotensin-aldosterone system blockade?","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.20452\/pamw.2089","article-title":"Dual blockade of the renin-angiotensin-aldosterone system in renal disease: what is the future? Authors' reply","volume":"124","author":"Lizakowski","year":"2014","journal-title":"Pol Arch Med Wewn"},{"key":"10.1053\/j.jrn.2014.10.026_bib65","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib66","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jrn.2014.10.026_bib67","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"}],"container-title":["Journal of Renal Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227614002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227614002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T02:08:18Z","timestamp":1747361298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227614002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1051227614002465"],"URL":"https:\/\/doi.org\/10.1053\/j.jrn.2014.10.026","relation":{},"ISSN":["1051-2276"],"issn-type":[{"type":"print","value":"1051-2276"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}